Waldenstrom Macroglobulinemia Clinical Trials

A listing of Waldenstrom Macroglobulinemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 65 clinical trials
featured
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL), Lymphoplasmacytic Lymphoma(LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma(SMZL)

(MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these

lymphoma
lymphocytosis
lymphadenopathy
marginal zone lymphoma
waldenstrom's macroglobulinemia
  • 88 views
  • 15 Apr, 2019
  • 1 location
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

blood transfusion
rituximab
anemia
thrombocytopenia
renal function tests
  • 92 views
  • 16 Jun, 2021
  • 60 locations
Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (MK-1026-003)

lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenstrm's macroglobulinemia (WM).

mantle cell lymphoma
leukemia
chronic lymphocytic leukemia
lymphoma
hepatitis b surface antigen
  • 0 views
  • 20 Jun, 2021
  • 9 locations
An Open-label Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).

  • 0 views
  • 13 Feb, 2021
  • 13 locations
Bendamustine Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

This is a multi-centre, open label, single-arm, phase II clinical trial in untreated patients with Waldenstrom's Macroglobulinemia. Symptomatic, previously untreated patients will receive SOC

  • 0 views
  • 14 May, 2021
  • 2 locations
Dasatinib In Waldenstr m Macroglobulinemia

This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenstrm Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK

platelet count
monoclonal protein
igm level
immunoglobulin
potassium
  • 2 views
  • 28 Jan, 2021
A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia

Hypothesis; That inhibition of plasma Blys by the monoclonal antibody Belimumab will reduce both the survival of the lymphoplasmacytoid cells of Waldenstrom Macroglobulinaemia (WM), and

  • 8 views
  • 08 Nov, 2020
  • 1 location
R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia

A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone followed by lenalidomide maintenance in patients with newly diagnosed Waldenstrm's macroglobulinemia

dexamethasone
rituximab
bortezomib
measurable disease
lenalidomide
  • 0 views
  • 26 Jan, 2021
  • 1 location
Zanubrutinib Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

This study aims to evaluate the efficacy of BTK inhibitor Zanubrutinib combined with Ixazomib and Dexamethasone (ZID) for the newly diagnosed Waldenstrom Macroglobulinemia. This ZID regimen will

cold agglutinin
cyclophosphamide
fludarabine
cytopenia
dexamethasone
  • 0 views
  • 24 Jan, 2021
  • 1 location
A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R WM will be evaluated in approximately 44 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.

  • 0 views
  • 24 Jan, 2021
  • 16 locations